Search
Position of EHA on the Harmonization of Training and Education in Europe
The challenge
Education and training are largely national competencies.
Registration & accommodation
Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.
Read moreEHA-EBMT 2nd European CAR T Cell Meeting
Dates: January 30 – February 1, 2020
Location: Sitges (Barcelona), Spain
Chairs: H Einsele, C Chabannon
The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.
Read moreEHA, AHA and GBMTA Successfully Conclude the First Joint Virtual Mini Hematology Tutorial
EHA-AHA-GBMTA Mini Hematology Tutorial
November 10-11, 2021
Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof YK Hakobyan (Armenian Hematology Association)
Dr T Kvatchadze (Georgian Association For Blood and Bone Marrow Transplantation)
EHA, the Armenian Hematology Association (AHA) and for the first time with the Georgian…
Lymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial
Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- »